Close menu




Biotech

Photo credits: pixabay.com

Commented by Stefan Feulner on December 18th, 2023 | 07:00 CET

Volkswagen, Desert Gold Ventures, Morphosys - Position for the rebound

  • Mining
  • Gold
  • Electromobility
  • Biotechnology

Last week's interest rate decision in the USA was the final starting signal for further price rises. In addition to equities, gold, silver, and several cryptocurrencies also shot up. Therefore, the last weeks of the year should end with further positive signs. Despite the record high in many indices, there are increasing rebound opportunities that could outperform the broad market in the near future.

Read

Commented by Stefan Feulner on December 13th, 2023 | 08:00 CET

Morphosys, Power Nickel, Nvidia - A pre-Christmas gift

  • Mining
  • Lithium
  • Biotechnology
  • chips

The stock market year 2023 brought with it a lot of volatility and no let-up in both geopolitical and fiscal policy upheavals. Nevertheless, Germany's leading index, the DAX, broke through to a new all-time high, while the precious metal gold also shot up to its highest level ever. On Monday, shareholders of the biotech company Morphosys also experienced a pre-Christmas gift, with an impressive gain of 30% at the end of the trading day.

Read

Commented by Fabian Lorenz on December 13th, 2023 | 07:30 CET

Several 100% upside potential? BioNTech, Bayer, Cardiol Therapeutics and Evotec in analyst check

  • Biotechnology
  • Pharma

We take a look at analysts' opinions on biotech and pharmaceutical stocks. Jefferies recently renewed its "Buy" recommendation for Evotec with a target price of EUR 34. The latest partnerships confirm that the Company's unique business model is working. The situation at Bayer is quite different. While the CEO is announcing radical changes, analysts are slashing their price targets, in some cases significantly. In contrast, analysts believe that Cardiol Therapeutics could achieve several 100% gains. The cash register is full to bursting, and an exciting news flow can be expected in 2024. At BioNTech, only the cash position is currently convincing. However, this is not enough for a buy recommendation.

Read

Commented by André Will-Laudien on December 12th, 2023 | 13:40 CET

Game Changer in Cancer - The Biotech Gold List for 2024! MorphoSys, Defence Therapeutics, BioNTech and Bayer

  • Biotechnology
  • Pharma
  • Cancer

The International Agency for Research on Cancer estimates the number of cancer deaths worldwide for the year 2022 to be around 10 million. However, the number of new cancer cases in the same year amounted to around 20 million, and cancer is still considered incurable. Lung cancer remains the sad frontrunner, claiming the most lives worldwide. Colorectal and stomach cancer follow at a considerable distance. However, since the original launch of the "Cancer Moonshot" in 2016, the fight against this incurable disease in the US has made some progress in the realization of therapies. Recently, there has been an increase in success stories from many biotech companies, and investors' enthusiasm is palpable once again. Where are the Biotech game changers lurking for the 2024 investment year?

Read

Commented by Armin Schulz on December 12th, 2023 | 06:50 CET

BioNTech, Defence Therapeutics, Bayer - Golden times for the biotech and pharma industry?

  • Biotechnology
  • Pharma
  • Covid19

With the arrival of winter, people are increasingly worried about illnesses such as coronavirus and influenza. The current wave of diseases and the new coronavirus variant are increasing the demand for medicines, which could positively impact the shares of pharmaceutical and biotech companies. Biotech's success in drug development for COVID-19 vaccines has allowed the industry to flourish over the past two years. But after the boom came the crash. However, the stock market always moves in cycles. The current challenges in the healthcare sector, such as the rising number of cancer cases, could, therefore, mean golden times for pharmaceutical and biotech companies, as they not only contribute to improving global health but also offer attractive returns for investors.

Read

Commented by Juliane Zielonka on December 8th, 2023 | 07:20 CET

Which stocks are leading the fight against cancer and chronic diseases? Defence Therapeutics, Merck and BioNTech

  • Biotechnology
  • Pharma

The pharmaceutical industry is facing complex developments in the fight against cancer, with Defence Therapeutics making significant progress with the successful FDA filing for its drug for the targeted treatment of tumors. The growing market opportunities in oncology until 2032 underline the potential of this breakthrough. In contrast, Merck KGaA is experiencing a severe setback with an 11% share price decline following the failure of evobrutinib for the relief of MS in late-stage clinical trials. According to analysts, this also impacts the Company's valuation. Despite promising cancer-fighting approaches, BioNTech faces uncertainties due to a reduced revenue forecast for 2023 and an 'Underweight' rating from JP Morgan. Despite these challenges, the sector remains dynamic. Find out which shares could be worthwhile in the long term here.

Read

Commented by Juliane Zielonka on December 7th, 2023 | 07:00 CET

New developments in the healthcare market: Cardiol Therapeutics, Amazon and Bayer shares in focus

  • Biotechnology
  • Pharma
  • Healthcare

Cardiol Therapeutics, a clinical-stage life sciences company focusing on therapies for heart inflammation, has secured a renowned clinic to advance its Phase II MAvERIC-Pilot study. This study, focused on combating recurrent pericarditis, promises to provide sound approaches to improve the quality of life of affected patients. Amazon has been dabbling in the healthcare sector since 2015 and is gradually conquering the telemedicine market. The path to telemedicine for Prime members, through the acquisition of companies such as "One Medical" and "PillPack", poses challenges. In contrast, Bayer is once again caught in the crossfire of legal disputes. The recent glyphosate trial loss before a jury in Philadelphia calls for a strategic realignment. At the same time, Bayer is attempting to provide new impetus in the area of women's health through a partnership in the field of hormonal contraception. Find out which development holds promise here.

Read

Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

  • Biotechnology
  • Pharma

Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.

Read

Commented by Armin Schulz on November 29th, 2023 | 06:30 CET

MorphoSys, Cardiol Therapeutics, Bayer - Where will the rebound start first?

  • Biotechnology
  • Pharma

2023 was a challenging year for pharmaceutical and biotech companies. After the boom years of the Corona pandemic, many companies went into a tailspin. But not just vaccine manufacturers were hit; others were dragged down too. The markets are currently volatile. MorphoSys has seen a peak gain of 145% since the beginning of the year - but is currently only up 35%. Cardiol Therapeutics has also gained over 140% and has recently consolidated. The share is currently up 74% since the beginning of the year. Only Bayer's performance curve is pointing downwards. The share is currently worth 34% less than on January 2. We look at where the rebound will start first after the consolidations.

Read

Commented by Fabian Lorenz on November 23rd, 2023 | 07:40 CET

Buy now? Morphosys, Siemens Energy and Desert Gold share

  • Mining
  • Gold
  • renewableenergies
  • Biotechnology

What do renewable energies, biotech and gold have in common? Shares from these sectors have predominantly experienced significant losses in 2023. Morphosys, Siemens Energy and Desert Gold are examples of this. However, the underperformers in the current year are often among the top performers in the upcoming year. Can this apply to these three shares? In the case of Morphosys, the latest study data has been confusing, and the share has given back its gains of the year. Analysts are now expressing their views. Siemens Energy has lost over 30% of its value due to operational problems, and the price targets of the experts vary widely. Explorer Desert Gold has been quiet recently. Is it the calm before a price jump? In any case, the share is anything but expensive.

Read